Clinical Trial Update: The Efficacy and Safety of Radiotherapy Plus Niraparib and Toripalimab in Patients With Recurrent Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating radiotherapy combined with niraparib and toripalimab for recurrent small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Niraparib (Niraparib)
• Toripalimab (Toripalimab)

Snippet

Sponsor: Wuhan University | Conditions: Recurrent Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN